» Articles » PMID: 31455237

Tamoxifen and Bone Morphogenic Protein-7 Modulate Fibrosis and Inflammation in the Peritoneal Fibrosis Model Developed in Uremic Rats

Overview
Journal Mol Med
Publisher Biomed Central
Date 2019 Aug 29
PMID 31455237
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Peritoneal fibrosis (PF) represents a long-term complication of peritoneal dialysis (PD), affecting peritoneal membrane (PM) integrity and function. Understanding the mechanisms underlying PF development in an uremic environment aiming alternative therapeutic strategies for treating this process is of great interest. The aim of this study was to analyze the effects of tamoxifen (TAM) and recombinant BMP7 (rBMP7) in an experimental model of PF developed in uremic rats.

Methods: To mimic the clinical situation of patients on long-term PD, a combo model, characterized by the combination of PF and CKD with severe uremia, was developed in Wistar rats. PF was induced by intraperitoneal (IP) injections of chlorhexidine gluconate (CG), and CKD was induced by an adenine-rich diet. Uremia was confirmed by severe hypertension, increased blood urea nitrogen (BUN> 120 mg/dL) and serum creatinine levels (> 2 mg/dL). Uremic rats with PF were treated with TAM (10 mg/Kg by gavage) or BMP7 (30 μg/Kg, IP). Animals were followed up for 30 days.

Results: CG administration in uremic rats induced a striking increase in PM thickness, neoangiogenesis, demonstrated by increased capillary density, and failure of ultrafiltration capacity. These morphological and functional changes were blocked by TAM or rBMP7 treatment. In parallel, TAM and rBMP7 significantly ameliorated the PM fibrotic response by reducing α-SMA, extracellular matrix proteins and TGF-ß expression. TAM or rBMP7 administration significantly inhibited peritoneal Smad3 expression in uremic rats with PF, prevented Smad3 phosphorylation, and induced a remarkable up-regulation of Smad7, an intracellular inhibitor of TGFβ/Smad signaling, contributing to a negative modulation of profibrotic genes. Both treatments were also effective in reducing local inflammation, possibly by upregulating IκB-α expression in the PM of uremic rats with PF. In vitro experiments using primary peritoneal fibroblasts activated by TGF-ß confirmed the capacity of TAM or rBMP7 in blocking inflammatory mediators, such as IL-1ß expression.

Conclusions: In conclusion, these findings indicate important roles of TGF-ß/Smad signaling in PF aggravated by uremia, providing data regarding potential therapeutic approaches with TAM or rBMP7 to block this process.

Citing Articles

High BMP7 Expression May Worsen Airway Disease in COPD by Altering Epithelial Cell Behavior.

Dong W, Xie M, Ming C, Li H, Xu X, Cui L Int J Chron Obstruct Pulmon Dis. 2025; 20():107-124.

PMID: 39802035 PMC: 11725281. DOI: 10.2147/COPD.S490537.


Peritoneal fibrosis: from pathophysiological mechanism to medicine.

Kang Y, Liu Y, Fu P, Ma L Front Physiol. 2024; 15:1438952.

PMID: 39301425 PMC: 11411570. DOI: 10.3389/fphys.2024.1438952.


Pathophysiological Mechanisms of Peritoneal Fibrosis and Peritoneal Membrane Dysfunction in Peritoneal Dialysis.

Ito Y, Sun T, Tawada M, Kinashi H, Yamaguchi M, Katsuno T Int J Mol Sci. 2024; 25(16).

PMID: 39201294 PMC: 11354376. DOI: 10.3390/ijms25168607.


Treatment of peritoneal fibrosis: Therapeutic prospects of bioactive Agents from Astragalus membranaceus.

Huang Y, Chu C, Mai Y, Zhao Y, Cao L, Ji S Front Pharmacol. 2024; 15:1347234.

PMID: 38835665 PMC: 11148558. DOI: 10.3389/fphar.2024.1347234.


Inhibition of STAT3 by S3I-201 suppress peritoneal fibroblast phenotype conversion and alleviate peritoneal fibrosis.

Song Q, Li H, Yan H, Yu Z, Li Z, Yuan J J Cell Mol Med. 2024; 28(10):e18381.

PMID: 38780509 PMC: 11114217. DOI: 10.1111/jcmm.18381.


References
1.
Allaria P, Giangrande A, Gandini E, Pisoni I . Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent?. J Nephrol. 2000; 12(6):395-7. View

2.
Ates K, Koc R, Nergizoglu G, Erturk S, Keven K, Sen A . The longitudinal effect of a single peritonitis episode on peritoneal membrane transport in CAPD patients. Perit Dial Int. 2000; 20(2):220-6. View

3.
Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F . Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem. 2001; 276(46):42908-14. DOI: 10.1074/jbc.M105316200. View

4.
Margetts P, Kolb M, Galt T, Hoff C, Shockley T, Gauldie J . Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol. 2001; 12(10):2029-2039. DOI: 10.1681/ASN.V12102029. View

5.
Williams J, Craig K, Topley N, Von Ruhland C, Fallon M, Newman G . Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002; 13(2):470-479. DOI: 10.1681/ASN.V132470. View